alovudine has been researched along with Ovarian Neoplasms in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Björkling, F; Erichsen, KD; Højgaard, L; Jensen, MM; Jensen, PB; Johnbeck, CB; Kjær, A; Madsen, J; Sehested, M | 1 |
| Morishita, F; Okazawa, H; Orisaka, M; Tsuyoshi, H; Yoshida, Y | 1 |
| Aide, N; Cullinane, C; Dorow, D; Hicks, RJ; Kinross, K; McArthur, G; Neels, O; Roselt, P; Waldeck, K | 1 |
| Björkling, F; Erichsen, KD; Højgaard, L; Jensen, MM; Jensen, PB; Kjær, A; Madsen, J; Sehested, M | 1 |
| Bencherif, B; DeLoia, JA; Edwards, RP; Elishaev, E; Krivak, TC; Mountz, JM; Richard, SD | 1 |
| Aboagye, EO; Gabra, H; Perumal, M; Stronach, EA | 1 |
| Björkling, F; Erichsen, KD; Højgaard, L; Jensen, PB; Kjær, A; Madsen, J; Munk Jensen, M; Sehested, M | 1 |
| Björkling, F; Bzorek, M; Erichsen, KD; Højgaard, L; Jensen, MM; Jensen, PB; Johnbeck, CB; Kjær, A; Madsen, J; Sehested, M | 1 |
| Aboagye, EO; Aerts, JL; Baird, SK; Lemoine, NR; Leyton, J; Lockley, M; McNeish, IA | 1 |
1 trial(s) available for alovudine and Ovarian Neoplasms
| Article | Year |
|---|---|
Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3'deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging.
Topics: Aged; Biological Transport; Biomarkers, Tumor; Cell Proliferation; Dideoxynucleosides; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Ovarian Neoplasms; Pilot Projects; Positron-Emission Tomography; Recurrence; Thymidine Kinase; Tomography, X-Ray Computed | 2011 |
8 other study(ies) available for alovudine and Ovarian Neoplasms
| Article | Year |
|---|---|
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
Topics: Animals; Antineoplastic Agents; Dideoxynucleosides; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Hydroxamic Acids; Ki-67 Antigen; Mice; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sulfonamides; Thymidine Kinase; Tumor Burden | 2013 |
18F-fluorothymidine PET is a potential predictive imaging biomarker of the response to gemcitabine-based chemotherapeutic treatment for recurrent ovarian cancer: preliminary results in three patients.
Topics: Aged; Biomarkers, Tumor; Deoxycytidine; Dideoxynucleosides; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Positron-Emission Tomography; Recurrence; Tomography, X-Ray Computed | 2013 |
18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Dideoxynucleosides; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Xenograft Model Antitumor Assays | 2010 |
Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.
Topics: Animals; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Chlorpropamide; Dideoxynucleosides; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Mice; Ovarian Neoplasms; Platinum; Positron-Emission Tomography; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
[18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Ki-67 Antigen; Mice; Ovarian Neoplasms; Positron-Emission Tomography; Thymidine Kinase; Time Factors; Tomography, X-Ray Computed; Treatment Failure; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
Topics: Acrylamides; Animals; Antineoplastic Agents; Biological Transport; Cell Proliferation; Clinical Trials, Phase II as Topic; Dideoxynucleosides; Drug Monitoring; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression; Humans; Ki-67 Antigen; Mice; Mice, Nude; Nicotinamide Phosphoribosyltransferase; Ovarian Neoplasms; Piperidines; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Cell Line, Tumor; Conserved Sequence; Dideoxynucleosides; Female; Fluorine Radioisotopes; Gene Deletion; Humans; Luciferases, Renilla; Luminescent Measurements; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Virus Replication; Xenograft Model Antitumor Assays | 2006 |